Ionis Pharmaceuticals, Inc. (IONS)
IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal
Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.
Ionis: Recent Approvals, Upcoming Catalysts To Spur Strong Upside (Rating Upgrade)
After years of futility, Ionis' recent regulatory and clinical successes have spurred optimistic market attention. I review Q2/2025 earnings documents together with 09/04/2025 CEO Monia interview and CORE and CORE2 Topline Results transcript for current investment prospects. IONS stock has a boatload of recent and near term upcoming market moving catalysts.
Ionis Pharmaceuticals, Inc. (IONS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.
Ionis Pharmaceuticals, Inc. (IONS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 10:15 AM EDT Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants Yanan Zhu - Wells Fargo Securities, LLC, Research Division Presentation Yanan Zhu Senior Equity Analyst Okay. Thank you, everyone, for being here.
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.
Ionis: Dawnzera Approval Kicks Off New Era For Strikingly Undervalued Pharma
Ionis Pharmaceuticals remains a Buy after Dawnzera's FDA approval, which strengthens its pipeline and revenue outlook despite a history of operating losses. Dawnzera's market opportunity in hereditary angioedema is significant, with potential for near-blockbuster status if it captures a 20% share of a ~$5bn market. Upcoming catalysts — including olezarsen's sHTG data and eplontersen's ATTR-CM results — could drive Ionis toward profitability and a higher valuation.
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
Ionis crushes Q2 estimates with EPS of $0.86 and sales of $452 million, lifting its 2025 revenue forecast and sending shares up 5%.
Ionis Pharmaceuticals, Inc. (IONS) Q2 2025 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q2 2025 Earnings Conference Call July 30, 2025 11:30 AM ET Company Participants Brett P. Monia - Founder, CEO & Director D.
Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings
While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates
Ionis Pharmaceuticals (IONS) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to a loss of $0.45 per share a year ago.
Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: Should You Buy?
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Buy Ionis Pharmaceuticals (IONS) After Golden Cross?
After reaching an important support level, Ionis Pharmaceuticals, Inc. (IONS) could be a good stock pick from a technical perspective. IONS recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
